Expression of Bcl2L12 in chronic lymphocytic leukemia patients: Association with clinical and molecular prognostic markers

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Karan Djurasevic, Teodora ^a   Palibrk, Vuk ^a   Zukic, Branka ^a   Spasovski, Vesna ^a   Glumac, Irena ^a   Colovic, Milica ^a   Colovic, Natasa ^a,b   Jurisic, Vladimir ^c   Scorilas, Andreas ^d   Pavlovic, Sonja ^a   Tosic, Natasa ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bcl2L12; CD38; Chronic lymphocytic leukemia; Expression analysis; IGHV mutational status; LPL

Indexed keywords

CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; LIPOPROTEIN LIPASE; PROTEIN BCL 2; PROTEIN BCL 2 LIKE 12; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUSCLE PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84871720560     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0405-7     Document Type: Article

References (29)

1. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200(4):519-25.
2. van Gent R, Kater AP, Otto SA, et al. In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. Cancer Res. 2008;68(24):10137-44.
3. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol. 2003;123(3):380-8.
4. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999;17:399-408.
5. Korz C, Pscherer A, Benner A, et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood. 2002;99(12):4554-61.
6. Proto-Siqueira R, Panepucci RA, Careta FP, et al. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood. 2008;112(2):394-7.
7. Zhuang J, Hawkins SF, Glenn MA, et al. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica. 2010;95(1):110-8.
8. Packham G, Stevenson FK. Bodyguards and assassins: bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology. 2005;114(4):441-9.
9. Saxena A, Viswanathan S, Moshynska O, et al. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol. 2004;75(1):22-33.
10. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996;69(2):114-9.
11. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1997;76(7):935-8.
12. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 1998;91(9):3379-89.
13. Scorilas A, Kyriakopoulou L, Yousef GM, et al. Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. Genomics. 2001;72(2):217-21.
14. Talieri M, Diamandis EP, Katsaros N, Gourgiotis D, Scorilas A. Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thromb Haemost. 2003;89(6):1081-8.
15. Kontos CK, Papadopoulos IN, Scorilas A. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. Biol Chem. 2008;389(12):1467-75.
16. Floro D, Papadopoulos IN, Scorilas A. Molecular analysis and prognostic impact of the novel apoptotic gene Bcl2L12 in gastric cancer. Biochem Biophys Res Commun. 2010;391:214-8.
17. Stegh AH, Kim H, Bachoo RM, et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev. 2007;21(1):98-111.
18. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-54.
19. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 2003;101(4):1262-9.
20. Nuckel H, Huttmann A, Klein-Hitpass L, et al. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2006;47(6):1053-61.
21. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood. 2008;111(12):5446-56.
22. Papageorgiou SG, Kontos CK, Pappa V, et al. The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker. Oncologist. 2011;16(9):1280-91.
23. Van Bockstaele F, Pede V, Janssens A, et al. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. Clin Chem. 2007;53(2):204-12.
24. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109(1):259-70.
25. Jurisic V, Colovic N, Kraguljac N, Atkinson HD, Colovic M. Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters. Med Oncol. 2008;25(3):315-22.
26. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4):1410-6.
27. Dürig J, Naschar M, Schmücker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia. 2002;16(1):30-5.
28. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-7.
29. van't Veer MB, Brooijmans AM, Langerak AW, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica. 2006;91(1):56-63.